Key Details
Last Dividend
$0.58Annual ROE
-108.46%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 11, 2021Recent annual earnings:
Mar 18, 2021Next ex-dividend date:
N/ARecent ex-dividend date:
June 21, 2023Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
22 Oct '21 HC Wainwright & Co.
Neutral22 Oct '21 Canaccord Genuity
Hold14 June '21 HC Wainwright & Co.
Buy12 Oct '20 RBC Capital
Outperform12 Oct '20 Jefferies
Buy12 Oct '20 Canaccord Genuity
BuyScreeners with MTCR included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Metacrine?
- What is the ticker symbol for Metacrine?
- Does Metacrine pay dividends?
- What sector is Metacrine in?
- What industry is Metacrine in?
- What country is Metacrine based in?
- When did Metacrine go public?
- Is Metacrine in the S&P 500?
- Is Metacrine in the NASDAQ 100?
- Is Metacrine in the Dow Jones?
- When was Metacrine's last earnings report?
- When does Metacrine report earnings?
- Should I buy Metacrine stock now?
What is the primary business of Metacrine?
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
What is the ticker symbol for Metacrine?
The ticker symbol for Metacrine is NASDAQ:MTCR
Does Metacrine pay dividends?
No, Metacrine does not pay dividends
What sector is Metacrine in?
Metacrine is in the Healthcare sector
What industry is Metacrine in?
Metacrine is in the Biotechnology industry
What country is Metacrine based in?
Metacrine is headquartered in United States
When did Metacrine go public?
Metacrine's initial public offering (IPO) was on 16 September 2020
Is Metacrine in the S&P 500?
No, Metacrine is not included in the S&P 500 index
Is Metacrine in the NASDAQ 100?
No, Metacrine is not included in the NASDAQ 100 index
Is Metacrine in the Dow Jones?
No, Metacrine is not included in the Dow Jones index
When was Metacrine's last earnings report?
Metacrine's most recent earnings report was on 11 November 2021
When does Metacrine report earnings?
The date for Metacrine's next earnings report has not been announced yet
Should I buy Metacrine stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions